Sandoz Commits to New UN Program to Combat Child Mortality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sandoz Commits to New UN Program to Combat Child Mortality


Sandoz has made a long-term commitment to supply a key antibiotic formulation as part of the United Nations' new Every Newborn Action Plan, which aims to eliminate preventable deaths of newborn and stillborn babies. The commitment involves providing long-term global supplies of amoxicillin 250 mg dispersible tablets to developing countries via the UN Commission for Lifesaving Commodities.

More than five million children under five are estimated to die worldwide every year, mainly in Africa and Asia, and nearly a quarter of those deaths are due to pneumonia alone, making it the single largest killer in that age range, a press release reported. In 2011, the World Health Organization updated its recommendations for home treatment of pneumonia, establishing dispersible amoxicillin as the newly recommended first-line treatment for pneumonia in children under five.

"Sandoz is proud to be jointly leading the response to the growing global need for this new formulation of a critical anti-infective", said Nick Haggar, head of Western Europe, Middle East, and Africa for Sandoz. "We are committed to working in partnership with all concerned to help prevent the needless deaths of hundreds of thousands of children every year. In our first year of supply, we hope to reach at least 500,000 children worldwide."

Sources: Sandoz

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here